Cord Blood vs Cord Tissue vs Placenta: Which Stem Cells Are Worth Storing?

Three things are available for collection at a single birth: the blood inside the umbilical cord, the cord tissue itself, and the placenta. They come from the same few minutes and they contain genuinely different cells with different uses.

Most banks will offer you all three as a bundle. This guide explains what each one actually contains, what it is proven to do, and what is still research, so you can judge whether a three-part package is worth what it costs. We store cord blood only. The reasoning behind that is set out below and you can disagree with it.

Cord Blood: Haematopoietic Stem Cells

Cord blood is rich in haematopoietic stem cells, the cells that rebuild blood and immune systems. They are the reason bone marrow transplants work, and cord blood is simply a younger, easier-to-collect source of the same cell type.

This is established transplant medicine, not emerging science. Cord blood stem cells are standard therapy for roughly 80 conditions, including leukaemia, lymphoma, thalassaemia, sickle cell disease, aplastic anaemia and a range of inherited immune and metabolic disorders. More than 60,000 cord blood transplants have been performed worldwide since the first in 1988. The patient treated in that first transplant is still alive.

Cord blood also has practical advantages over bone marrow. It is available immediately rather than requiring a donor search, it tolerates a less exact tissue match, and it carries a lower rate of graft-versus-host disease.

One honest limitation applies. A child’s own cord blood cannot be used to treat that child’s genetic disease or, generally, that child’s leukaemia, because the stored cells carry the same genetic variant or pre-malignant cells. The clinical value of a privately stored unit usually lies with a sibling or matched relative. We cover this in more detail in our guide to cord blood myths and facts [LINK PENDING: article two].

Cord Tissue: Mesenchymal Stromal Cells

The umbilical cord itself contains Wharton’s jelly, a gel-like connective tissue rich in mesenchymal stromal cells, usually shortened to MSCs. These are a completely different cell type from the ones in cord blood. They do not rebuild blood. They modulate inflammation and support tissue repair, which is why they are studied for cartilage, bone, muscle, nerve and autoimmune conditions.

The science is real and it is moving. Hundreds of registered clinical trials are investigating MSCs from cord tissue, and in December 2024 the first MSC therapy in history was approved by the US FDA: Ryoncil, for steroid-refractory acute graft-versus-host disease in children.

Read the detail of that approval carefully, because it is the most important fact in this article. Ryoncil is made from the bone marrow of healthy adult donors and manufactured as an off-the-shelf product. It is not a retrieved personal sample. Nobody’s privately banked tissue was involved.

That is how the whole field is developing. Manufacturers build master cell banks from screened donors and scale production to consistent, tested batches. Even the clinics offering Wharton’s jelly treatments today use donor allograft material rather than a patient’s own stored tissue.

So the question to ask before paying for cord tissue storage is not whether MSC medicine will work. It probably will. The question is whether a future therapy will use your child’s specific banked sample, when the industry is visibly building the opposite model. No cord tissue treatment is currently approved anywhere.

Placenta: More MSCs, Plus Growth Factors

The placenta is the largest of the three sources by volume and yields MSCs in high numbers, alongside amniotic membrane and a range of growth factors and signalling proteins. Placental and amniotic products are already used in wound care and some orthopaedic applications, and are under investigation for neurological conditions.

Two things are worth separating, because banks tend to blur them. Placental and amniotic tissue products in clinical use today are donor-derived, processed, regulated products, the same manufacturing model as Ryoncil. Private placental storage for your own family’s future use is a different proposition entirely, and it sits at an earlier stage of evidence than cord tissue, which is itself earlier than cord blood.

Placenta is the most speculative of the three. That does not make it worthless. It makes it a purchase you should make with clear eyes about what you are buying, which is optionality on a research field, not access to a treatment.

Side by Side

The pattern in that table is the whole answer. As you move from cord blood to cord tissue to placenta, the biology gets more interesting and the evidence gets thinner. Price usually moves in the opposite direction to evidence, because bundles are sold on potential rather than proof.

So What Should You Store?

Our position, and you should weigh it knowing what we sell:

• Cord blood is the part with proven clinical use.If you store one thing, store this. It is the only one of the three with an established transplant record and defined treatable conditions.
• Cord tissue and placenta are bets on a delivery model.Not on whether MSC medicine works, but on whether it will ever be delivered from your personal sample rather than from a manufactured donor product. Current evidence points the other way.
• If a bank quotes one price for all three, ask for them separately.You are entitled to know what the tissue and placenta components cost on their own before deciding whether that part is worth it.

Abu Dhabi Biobank stores cord blood only, at a published price, from AED 7,500 inclusive of VAT for 30 years . That is a deliberate choice rather than a gap in the range.

We are working on MSC medicine at the level where the evidence says it will actually be delivered. Our partnership with Human Life CORD Japan is developing manufactured umbilical cord-derived therapies for the UAE and wider region, sourced through public donation . If cord-derived MSC therapy becomes standard care here, that is the route by which families will reach it.

If you want to talk it through, speak to our medical advisors . Unfamiliar terms are explained in our glossary .